Concepedia

James Tumlin

JT

Statistics

Publications

4

Citations

360

H-Index

4

Active since

2022

Affiliations

AstraZeneca (United States)(Current)

The Ohio State University Wexner Medical Center

Radboud University Medical Center

Alexion Pharmaceuticals (United States)

University of Leicester

James Tumlin is an author at AstraZeneca (United States) specializing in renal disease, nephrology, and renal pathophysiology.

Publications per year

2022–2024

4

Publications

4

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies

Carla Nester, Gerald B. Appel, Andrew S. Bomback et al. · American Journal of Nephrology · 2022 · 65 citations · Full text

Medicine, Immunology, Nephrology +17

Efficacy and Safety of Ravulizumab in IgA Nephropathy

Richard Lafayette, James Tumlin, Roberta Fenoglio et al. · Journal of the American Society of Nephrology · 2024 · 58 citations · Full text

Life Sciences, Nephrology, Pharmacotherapy +17

Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan

Steven D. Podos, Howard Trachtman, Gerald B. Appel et al. · American Journal of Nephrology · 2022 · 22 citations · Full text

Medicine, Nephrology, Pathology +17

1–4 of 4